Skip to main content
. Author manuscript; available in PMC: 2018 Aug 14.
Published in final edited form as: Cancer Cell. 2017 Aug 14;32(2):253–267.e5. doi: 10.1016/j.ccell.2017.07.006

Figure 2. Immunohistochemical staining of immune cell markers after G47.

Figure 2

(A–B) Δ-mIL12 treatment. (A–B) 005 GSCs (2 × 104) implanted on day 0, injected intratumorally (IT) with G47Δ-mIL12 (1 × 105 pfu; n=3) or PBS (n=4) on days 18 and 24, animals sacrificed on day 25, and brains collected. Brain tumor sections were stained as indicated. For PD-L1 brain sections, 005 GSCs (2 × 104) implanted on day 0, injected IT with G47Δ-mIL12 (5 × 105 pfu; n=3) or PBS (n=3) on days 17, animals sacrificed on day 24, and brain tumor sections stained with anti-PD-L1 antibody. Representative images are presented; scale bar=100 μm (A). The number of positive cells from 3–9 fields/tumor section (1 section/mouse, except 3 for CD3) were counted (B). Average number of positive cells from each individual mouse is identified by symbol and color. The mean ± SEM of all mice is presented. Data were assessed by Student’s t test; *p<0.05; **p<0.001. See also Figure S1.